If lymph node involvement is proven in the patient going through neoadjuvant therapy who is a potential prospect for specific axillary dissection (TAD), a marker needs to be inserted in the lymph node just after biopsy. However, micrometastases are excluded from this risk class. This also applies to the https://archbishopq663ryg0.bloggerbags.com/profile